Among alternative antigens (including CD19, CD22, CD37, and CD79B), CD19 seems to be the most qualified one because of its expression in B-cell lymphomas and leukemias and its absence on a wide spectrum of irrelevant healthy tissues alongside plasma cells and hematopoietic stem cells [3]. This evidence concerns the gene CD19 and leukemia.